Amyloidosis

CHICAGO — Vutrisiran improved mortality and recurrent CV risks independent of disease severity and improved several other endpoints for a broad spectrum of patients with transthyretin amyloidosis with cardiomyopathy, subgroup analyses show.

Patients beginning lung cancer treatment demonstrated a high prevalence of atherosclerosis, which suggests that they may benefit from calcium scoring, new data showed.

Healio spoke with Chakra Chaulagain, MD, about phase 3 PERSEUS trial results presented at ASH 2023.

The FDA rejected a supplemental new drug application for patisiran to treat cardiomyopathy of wild-type transthyretin-mediated or hereditary transthyretin-mediated amyloidosis, citing insufficient evidence of clinical meaningfulness.

An FDA panel voted 9-3 in favor of expanding approval of patisiran to patients with cardiomyopathy of wild-type transthyretin-mediated or hereditary transthyretin-mediated amyloidosis, noting modest benefits but no significant safety concerns.

PHILADELPHIA — In this Healio video exclusive, Yehuda Handelsman, MD, FACP, FNLA, FASCP, MACE, co-chair of the Heart in Diabetes CME Conference, discusses the mission and purpose of the meeting.

NEW ORLEANS — Black female carriers of the V122I genetic variant for cardiac amyloidosis have substantially higher CVD and all-cause mortality risk, which grows with age, compared with noncarriers, researchers reported.